PortfoliosLab logo
IDEAYA Biosciences, Inc. (IDYA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US45166A1025

CUSIP

45166A102

IPO Date

May 23, 2019

Highlights

Market Cap

$1.79B

EPS (TTM)

-$3.36

Total Revenue (TTM)

$7.00M

Gross Profit (TTM)

$5.26M

EBITDA (TTM)

-$274.69M

Year Range

$13.45 - $44.42

Target Price

$52.27

Short %

14.38%

Short Ratio

7.06

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in IDEAYA Biosciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


50.00%100.00%150.00%200.00%December2025FebruaryMarchAprilMay
55.67%
100.55%
IDYA (IDEAYA Biosciences, Inc.)
Benchmark (^GSPC)

Returns By Period

IDEAYA Biosciences, Inc. (IDYA) returned -32.22% year-to-date (YTD) and -57.14% over the past 12 months.


IDYA

YTD

-32.22%

1M

10.39%

6M

-44.31%

1Y

-57.14%

5Y*

20.54%

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.77%

1M

3.72%

6M

-5.60%

1Y

8.55%

5Y*

14.11%

10Y*

10.45%

*Annualized

Monthly Returns

The table below presents the monthly returns of IDYA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-5.25%-15.52%-20.37%22.89%-13.46%-32.22%
202422.34%2.69%-1.83%-7.36%-10.09%-3.94%22.61%-8.25%-19.80%-11.14%-2.81%-6.07%-27.77%
2023-6.27%3.64%-22.21%32.99%25.08%2.89%-4.85%31.31%-8.11%0.70%15.75%13.13%95.82%
2022-29.91%-20.34%-15.23%-14.30%16.27%23.77%8.12%-34.12%51.78%13.20%5.86%1.62%-23.14%
202125.57%8.48%23.23%-12.55%-1.95%4.17%16.72%-4.08%8.47%-15.89%2.61%7.45%68.86%
202014.00%-18.13%-41.14%34.71%76.40%45.15%-11.26%-4.04%3.80%-3.11%14.54%0.43%86.67%
20196.08%-16.09%-28.61%-4.36%32.35%-37.00%34.92%-1.96%-32.98%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of IDYA is 4, meaning it’s performing worse than 96% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of IDYA is 44
Overall Rank
The Sharpe Ratio Rank of IDYA is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of IDYA is 33
Sortino Ratio Rank
The Omega Ratio Rank of IDYA is 55
Omega Ratio Rank
The Calmar Ratio Rank of IDYA is 44
Calmar Ratio Rank
The Martin Ratio Rank of IDYA is 55
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for IDEAYA Biosciences, Inc. (IDYA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

IDEAYA Biosciences, Inc. Sharpe ratios as of May 10, 2025 (values are recalculated daily):

  • 1-Year: -1.07
  • 5-Year: 0.29
  • All Time: 0.10

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of IDEAYA Biosciences, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2025FebruaryMarchAprilMay
-1.07
0.44
IDYA (IDEAYA Biosciences, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


IDEAYA Biosciences, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%December2025FebruaryMarchAprilMay
-63.04%
-7.88%
IDYA (IDEAYA Biosciences, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the IDEAYA Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the IDEAYA Biosciences, Inc. was 74.64%, occurring on Mar 17, 2020. Recovery took 63 trading sessions.

The current IDEAYA Biosciences, Inc. drawdown is 63.04%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-74.64%May 30, 2019202Mar 17, 202063Jun 16, 2020265
-69.42%Sep 23, 2021158May 9, 2022323Aug 22, 2023481
-69.23%Feb 20, 2024285Apr 8, 2025
-39.58%Jun 18, 202046Aug 21, 2020102Jan 19, 2021148
-30.49%Apr 6, 202166Jul 8, 202140Sep 2, 2021106

Volatility

Volatility Chart

The current IDEAYA Biosciences, Inc. volatility is 20.37%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%December2025FebruaryMarchAprilMay
20.37%
6.82%
IDYA (IDEAYA Biosciences, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of IDEAYA Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of IDEAYA Biosciences, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -121.3%.


-1.50-1.00-0.500.000.501.001.502.0020212022202320242025
-1.49
-0.67
Actual
Estimate

Valuation

The Valuation section provides an overview of how IDEAYA Biosciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for IDYA relative to other companies in the Biotechnology industry. Currently, IDYA has a P/S ratio of 256.1. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for IDYA in comparison with other companies in the Biotechnology industry. Currently, IDYA has a P/B value of 1.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items